CGEM News and Press, Cullinan Oncology Inc. From 02/02/23

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will pa...

Cullinan Oncology ( NASDAQ: CGEM ) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application seeking to start a trial of blood cancer drug CLN-978. The company will initially evaluate CLN-978 in a phase 1 trial to treat patients with ...

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) app...

Cullinan Oncology press release ( NASDAQ: CGEM ): Q3 GAAP EPS of -$0.54 beats by $0.43 . Cash and investments of approximately $607 million as of September 30, 2022 For further details see: Cullinan Oncology GAAP EPS of -$0.54 beats by $0.43

Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92% Continued enrollment in CLN-049 and CLN-619 clinical studies with initial clinical data updates on track for mid-20...

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointe...

Cullinan Oncology ( NASDAQ: CGEM ) on Tuesday said it increased its ownership in its subsidiary Cullinan MICA (MICA) to 92% from 54% for $30.7M. Cullinan raised its ownership by buying equity from two of MICA's financial investors, Avalon Ventures and Br...

Cullinan increases ownership in MICA subsidiary from 54% to 92% through share purchase from existing financial investors The ongoing Phase I clinical trial for CLN-619 remains on track to report initial clinical data in mid-2023 CAMBRIDGE, Mass., Oct. 25, 2022 (GLOBE NEWSW...

Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ...

Summary Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after. Robust cash position (runway through 2026) allows them to prosecute clinical programs more...